Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Osteosarcoma 4Neuroblastoma 3Sarcoma, Ewing 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Medulloblastoma 1Leiomyosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Bone Neoplasms 1

Interventions

Temozolomide 4Irinotecan 3abemaciclib 2Radiotherapy 2Cyclophosphamide 2Bevacizumab 2palbociclib 1dostarlimab 1dinutuximab 1adavosertib 1Vorinostat 1Vincristine 1Valproic Acid 1Topotecan 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiation 1Mebendazole 1Granulocyte-Macrophage Colony-Stimulating Factor 1Etoposide 1Eflornithine 1Carboplatin 1CLR1404 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × dinutuximab × Sarcoma × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡